Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
G. Liu
Observed names:
Gengyuan Liu,
Liu, Gengyuan
Institutions:
Beijing Normal University,
HBIS (China)
Observed institutions:
University of Science and Technology of China,
University Health Network,
University of Toronto,
Beijing Normal University,
Princess Margaret Cancer Centre,
Bristol-Myers Squibb (United States),
HBIS (China)
show all 7
OpenAlex ID:
A5113966020
Integrating hybrid life cycle assessment to quantify carbon footprint in mariculture: Overcoming truncation errors and unveiling macroeconomic drivers
2026
·
Ting Jiang
, Kangni Wu
, et al.
·
Environmental Impact Assessment Review
·
9
Data-driven strategies for increasing patient diversity in Bristol Myers Squibb–sponsored US oncology clinical trials
2023
·
Lorena Kuri
, Sagar Setru
, et al.
·
Clinical Trials
·
8
PDF
IL-4-secreting CD40L+ MAIT cells support antibody production in the peripheral blood of Heonch–Schönlein purpura patients
2023
·
Tengchuan Jin
, Muziying Liu
, et al.
·
Inflammation Research
·
6
PDF
Predicting abatacept retention using machine learning
2025
·
Rieke Alten
, Claire Behar
, et al.
·
Arthritis Research & Therapy
·
4
PDF
From symbiosis to co-prosperity: Redefining industry-city integration for urban resilience
2026
·
Yunsheng Bai
, Gengyuan Liu
, et al.
·
Environmental Impact Assessment Review
·
3
P59.17 EGFR Mutation Status, Liver Metastasis, and Overall Survival in Advanced Lung Adenocarcinoma Patients
2021
·
P. Walia
, L. Zhan
, et al.
·
Journal of Thoracic Oncology
·
3
PDF
MA11.08 Patient-Reported Outcomes from the Randomized Phase 3 CROWN Study of First-Line Lorlatinib versus Crizotinib in ALK+ NSCLC
2021
·
J. Mazieres
, L. Iadeluca
, et al.
·
Journal of Thoracic Oncology
·
3
FP01.03 Prevalence, Treatment Patterns and Long-Term Clinical Outcomes of Patients with EGFR Positive Resected Stage IB-IIIA NSCLC
2021
·
S. Schmid
, M. Garcia
, et al.
·
Journal of Thoracic Oncology
·
2
PDF
MA08.02 Outcomes of Early Stage ALK-positive NSCLC patients in a Real-World Cohort
2021
·
S. Schmid
, S. Chotai
, et al.
·
Journal of Thoracic Oncology
·
2
FP12.01 PD-L1 Assessment in Cytology is Comparable to Histology in Predicting Treatment Response to Checkpoint Inhibitors in NSCLC
2021
·
S. Lau
, M. Rabindranath
, et al.
·
Journal of Thoracic Oncology
·
1
P64.01 The Canadian Small Cell Lung Cancer Database (CASCaDe): A Multi-Institutional Real-World Evidence Collaboration
2021
·
S. Moore
, J. Agulnik
, et al.
·
Journal of Thoracic Oncology
·
1
PDF
MA18.07 Identification of Neuroendocrine Transformation in Anaplastic Lymphoma Kinase Rearranged (ALK+) Tumors After Tyrosine Kinase Inhibitors
2019
·
P. Pal
, A. Fares
, et al.
·
Journal of Thoracic Oncology
·
1
P1.11.36 Strengthening Real World Evidence Generation Through an Expanding Multicenter Canadian Lung Cancer Registry
2025
·
P. Wheatley-Price
, L.C. Young
, et al.
·
Journal of Thoracic Oncology
EP03.01-002 Co-occurring Mutations, Smoking Status and Prognosis of Early-stage Resected NSCLCs with EGFR Mutations
2022
·
A. Moore
, E. Pianarosa
, et al.
·
Journal of Thoracic Oncology
P45.09 Real-World Sequencing of ALK-TKIs in Advanced Stage ALK-positive NSCLC patients in Canada
2021
·
S. Chotai
, S. Schmid
, et al.
·
Journal of Thoracic Oncology
FP12.07 Clinico-demographic Factors, EGFR status and their association with Stage at Diagnosis in Lung Adenocarcinoma Patients
2021
·
J. Herman
, S. Schmid
, et al.
·
Journal of Thoracic Oncology
P45.05 Sequencing of PD-1 Inhibitors and TKIs in Metastatic NSCLC with MET Exon 14 Skipping Mutation May Influence Survival
2021
·
S. Lau
, K. Perdrizet
, et al.
·
Journal of Thoracic Oncology
P45.07 Real-World Clinically-Relevant Toxicities of ALK TKIs in a Cohort of Patients With Advanced/Metastatic ALK+ NSCLC
2021
·
S. Schmid
, S. Chotai
, et al.
·
Journal of Thoracic Oncology
PDF
P14.24 Evolution of TCR Clonality during Chemoradiation and Durvalumab as Predictors of Survival in Stage 3 NSCLC
2021
·
S. Lau
, S. Soleimani
, et al.
·
Journal of Thoracic Oncology
PDF
P76.84 EGFR Status, Risk Factors for Brain Metastases and Overall Survival in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients
2021
·
M. Chowdhury
, K. Hueniken
, et al.
·
Journal of Thoracic Oncology
P1.01-30 Non-Small Cell Lung Cancer (NSCLC) Next Generation Sequencing (NGS): Integrating Genomic Sequencing into a Publicly Funded Health Care Model
2019
·
K. Perdrizet
, T. Stockley
, et al.
·
Journal of Thoracic Oncology
PDF
P2.14-62 Early, Subclinical SCLC Transformation in Patients with EGFR Mutant Lung Cancer Receiving Osimertinib, Detected Through Cell-Free DNA
2019
·
E. Stewart
, S. Martins-Filho
, et al.
·
Journal of Thoracic Oncology
P1.01-70 Dominant Circulating Myeloid Populations Are Associated with Poor Response in NSCLC Treated with 1st Line PD-1 Monotherapy
2019
·
S. Lau
, L. Le
, et al.
·
Journal of Thoracic Oncology
P2.03-37 Genomic Landscape of EGFR/ALK Wild-Type Lung Adenocarcinomas in Never-Smokers and Importance of Epithelial-Mesenchymal-Transition
2019
·
A. Fares
, S. Martins-Filho
, et al.
·
Journal of Thoracic Oncology
PDF
P2.14-40 Tumor-Stromal Microenvironment Interactions in a PDX Model of EGFR TKI Drug Tolerance
2019
·
E. Stewart
, R. Navab
, et al.
·
Journal of Thoracic Oncology
Show more works
View as search
Works count:
28
Citation count:
43
H-index:
4
I10-index:
Year
Topic
Type